Payment overview · 2025
General Payments
$178.43
10 reported records · 3 companies
Healthcare provider profile · identity verified
Bryce A Robison, MD
Allopathic & Osteopathic Physicians|Family Medicine · SIOUX CITY, IA · NPI 1235190968
Verified facts
What the public records show
CMS Open Payments records show Bryce A Robison, MD received $178.43 in general payments during 2025 across 10 reported records.
PFIZER INC. accounted for 70.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 212 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 212 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $125.91 | 70.6% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $37.19 | 20.8% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.33 | 8.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $178.43 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $125.91 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $37.19 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $37.19 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $15.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 212 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
212 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
212 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 798 | 175 |
| Atorvastatin Calcium | Atorvastatin Calcium | 684 | 180 |
| Amlodipine Besylate | Amlodipine Besylate | 577 | 151 |
| Omeprazole | Omeprazole | 496 | 121 |
| Lisinopril | Lisinopril | 478 | 125 |
| Hydrochlorothiazide | Hydrochlorothiazide | 416 | 104 |
| Metoprolol Succinate | Metoprolol Succinate | 394 | 101 |
| Losartan Potassium | Losartan Potassium | 316 | 89 |
| Furosemide | Furosemide | 277 | 82 |
| Metformin Hcl | Metformin Hcl | 273 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 268 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 241 | 57 |
| Sertraline Hcl | Sertraline Hcl | 231 | 48 |
| Warfarin Sodium | Warfarin Sodium | 218 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 215 | 47 |
| Eliquis | Apixaban | 212 | 30 |
| Gabapentin | Gabapentin | 205 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 196 | 64 |
| Simvastatin | Simvastatin | 179 | 51 |
| Escitalopram Oxalate | Escitalopram Oxalate | 178 | 43 |
| Lorazepam | Lorazepam | 175 | 49 |
| Metformin Hcl Er | Metformin Hcl | 173 | 46 |
| Azithromycin | Azithromycin | 158 | 139 |
| Tramadol Hcl | Tramadol Hcl | 156 | 57 |
| Meloxicam | Meloxicam | 143 | 53 |
| Glipizide Er | Glipizide | 130 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 113 | 24 |
| Prednisone | Prednisone | 113 | 49 |
| Spironolactone | Spironolactone | 109 | 31 |
| Carvedilol | Carvedilol | 104 | 25 |
| Trazodone Hcl | Trazodone Hcl | 104 | 24 |
| Allopurinol | Allopurinol | 103 | 33 |
| Alprazolam | Alprazolam | 103 | 22 |
| Potassium Chloride | Potassium Chloride | 101 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 101 | 23 |
| Cephalexin | Cephalexin | 95 | 78 |
| Pravastatin Sodium | Pravastatin Sodium | 89 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 86 | 31 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 86 | 70 |
| Methylprednisolone | Methylprednisolone | 86 | 78 |
| Benazepril Hcl | Benazepril Hcl | 84 | 23 |
| Finasteride | Finasteride | 83 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 79 | 26 |
| Farxiga | Dapagliflozin Propanediol | 76 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 75 | 28 |
| Cefdinir | Cefdinir | 72 | 62 |
| Jardiance | Empagliflozin | 68 | 16 |
| Montelukast Sodium | Montelukast Sodium | 68 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 62 | 17 |
| Ezetimibe | Ezetimibe | 61 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 58 | 16 |
| Risperidone | Risperidone | 56 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 56 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 14 |
| Ibuprofen | Ibuprofen | 53 | 13 |
| Atenolol | Atenolol | 52 | 14 |
| Clonazepam | Clonazepam | 50 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | suppressed |
| Bupropion Xl | Bupropion Hcl | 47 | 20 |
| Buspirone Hcl | Buspirone Hcl | 44 | suppressed |
| Ozempic | Semaglutide | 44 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 44 | suppressed |
| Memantine Hcl | Memantine Hcl | 41 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 40 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 39 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | suppressed |
| Gemfibrozil | Gemfibrozil | 37 | suppressed |
| Glipizide | Glipizide | 36 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 35 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | 12 |
| Famotidine | Famotidine | 34 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 32 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 31 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Ramipril | Ramipril | 30 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 27 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 19 |
| Fluconazole | Fluconazole | 25 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Colchicine | Colchicine | 24 | 14 |
| Nystatin | Nystatin | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 23 |
| Glimepiride | Glimepiride | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 19 |
| Diltiazem 24hr Er | Diltiazem Hcl | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | 14 |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 13 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Loperamide | Loperamide Hcl | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 14 |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 13 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Vytorin | Ezetimibe/Simvastatin | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Mesalamine | Mesalamine | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $178.43 · 10 records | PFIZER INC. | CAMZYOS, ELIQUIS, QULIPTA, UBRELVY | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error